J.P. Morgan: Eylea HD use expands: Can Merck’s ophthalmology pipeline catch up?
JPMorgan believes expanded indications and dosing regimens will support continued growth for Eylea HD, although declines in the original Eylea will offset some of that growth. Whether competition from new drugs can change the landscape also depends on payer restrictions and clinical advantages.